NATIONAL ELECTRICAL MANUFACTURERS ASSOCIATION for NATIONAL ELECTRICAL MANUFACTURERS ASSOCIATION
What was lobbied
9 issue areas, each in the filer's own words, with who lobbied on it and where.
Energy/Nuclear ENG
Advocacy on both S. 1260 United States Innovation and Competition Act of 2021 and H.R. 4521 America COMPETES Act of 2022 to support U.S. manufacturing competition in the global marketplace
| Lobbyist | Covered position, as disclosed |
|---|---|
| MADELEINE BUGEL | — |
Environment/Superfund ENV
Preparation for and meeting with EPA officials on the Toxic Substances Control Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| LAURA SREBNIK | — |
Health Issues HCR
Advocacy on PDUFA and GDUFA user fee legislation/regulation seeking to maintain certain exemptions for positron emission tomography imaging drugs Advocacy on H.R. 7253, the Clarifying Remanufacturing to Protect Patient Safety Act, seeking clarification the definition of remanufacturing, education and inspections; advocacy on cybersecurity vulnerabilities of legacy medical imaging devices; advocacy on artificial intelligence and need for reimbursement pathway; advocacy on focused ultrasound and need for improved coverage pathways and research funding; advocacy on medical device user fees
| Lobbyist | Covered position, as disclosed |
|---|---|
| SUSAN KATHLEEN BUNNING | — |
| HOLLY GROSHOLZ | — |
Labor Issues/Antitrust/Workplace LBR
Raising awareness to Congress regarding potential negative-job impact of DOE rule on GSL backstop implementation
| Lobbyist | Covered position, as disclosed |
|---|---|
| PETER FERRELL | — |
Manufacturing MAN
Support Buy American guidance for Infrastructure Investment and Jobs Act (IIJA) implementation that will allow electroindustry companies to qualify for federal assistance from the IIJA
| Lobbyist | Covered position, as disclosed |
|---|---|
| MADELEINE BUGEL | — |
Medicare/Medicaid MMM
Advocacy on HR 4479/S 2609, The FIND Act, seeking separate reimbursement for radiopharmaceuticals in the Medicare hospital outpatient setting. Advocacy on the CMS Final Decision regarding appropriate coverage for Monoclonal Antibody therapies and PET diagnostics.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SUSAN KATHLEEN BUNNING | — |
Science/Technology SCI
Advocacy on both S. 1260 United States Innovation and Competition Act of 2021 and H.R. 4521 America COMPETES Act of 2022 to support U.S. manufacturing competition in the global marketplace
| Lobbyist | Covered position, as disclosed |
|---|---|
| MADELEINE BUGEL | — |
Tariff (miscellaneous tariff bills) TAR
Advocacy on both S. 1260 United States Innovation and Competition Act of 2021 and H.R. 4521 America COMPETES Act of 2022 to support U.S. manufacturing competiveness in the global marketplace
| Lobbyist | Covered position, as disclosed |
|---|---|
| MADELEINE BUGEL | — |
Trade (domestic/foreign) TRD
Advocacy on both S. 1260 United States Innovation and Competition Act of 2021 and H.R. 4521 America COMPETES Act of 2022 to support U.S. manufacturing competiveness in the global marketplace
| Lobbyist | Covered position, as disclosed |
|---|---|
| MADELEINE BUGEL | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.